How well does the HPV vaccine protect adolescents?
The HPV vaccine is extremely effective at preventing the infections and diseases it targets. A 10-year follow-up study of 9- to 15-year-olds who received the 9-valent HPV vaccine found zero cases of high-grade cervical, anal, or genital lesions or genital warts caused by the nine HPV types covered by the vaccine [1]. This means that over a decade after vaccination, the protection held up completely.
Real-world data backs this up. A review of multiple studies found that the bivalent vaccine is 93–98% effective against moderate to severe cervical lesions caused by HPV types 16 and 18, and the quadrivalent vaccine reduced infections from HPV types 6, 11, 16, and 18 by about 90% [4]. The 9-valent vaccine, which covers five additional high-risk types, maintained at least 90% efficacy for 10–12 years [4]. These numbers translate to a dramatic reduction in the risk of cervical cancer and other HPV-related cancers when the vaccine is given before exposure to the virus.
Is the HPV vaccine safe for adolescents?
Yes, the safety profile of the HPV vaccine is well established. A large study in Taiwan that tracked over 12- to 15-year-old girls for up to 6 years found no statistically significant increase in the risk of 19 serious adverse events, including autoimmune diseases, neurological conditions, and blood clots, after HPV vaccination [5]. The study concluded there was no association between the vaccine and these serious events.
Clinical trials also confirm safety. In a randomized trial of the COVID-19 vaccine in adolescents (which used similar safety monitoring), the HPV vaccine has been studied in thousands of participants. A review of HPV vaccine trials and post-licensure surveillance reports that most side effects are mild and temporary, such as injection-site pain, swelling, fatigue, and headache [4]. Serious adverse events were rare and occurred at similar rates in vaccinated and placebo groups [4]. This means the vaccine is not linked to any long-term or severe health problems.
Why is it recommended to start the HPV vaccine series at age 9 or 11?
Starting the vaccine series early—at age 9 or 11—maximizes protection and improves completion rates. A study using 2020 U.S. national data found that adolescents who started the HPV vaccine at ages 9–10 had a 93% completion rate by age 13, compared to only 66% for those who started at ages 11–12 [3]. Starting early also means fewer missed opportunities: another study showed that 35–37% of adolescents who did not get the HPV vaccine at ages 9–10 never had a well visit at ages 11–12, so delaying the first dose can mean it never happens [2].
The immune response is also stronger in younger adolescents. A study of the 9-valent HPV vaccine found that 9- to 15-year-olds produced higher antibody levels than young adults, and these levels remained high for at least 10 years [1]. This means the vaccine works even better when given early, and the protection lasts through the ages when HPV exposure risk increases.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 2 from 2024 or later, 1 in Q1 journals, collectively cited 71 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 83 papers retrieved from a database of over 500 million.
Sources used in this answer
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety
A 10-year follow-up of 1,272 adolescents who received the 9-valent HPV vaccine found zero cases of HPV-related high-grade lesions or genital warts, with sustained antibody levels and seropositivity rates ≥81%.
Human papillomavirus vaccine administration opportunities at well visits in adolescents.
A retrospective analysis of U.S. insurance claims found that 89–92% of 9-year-old well visits had no vaccine claims, and that starting HPV vaccination at age 9 could capture many adolescents who later miss well visits at ages 11–12.
Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
Using 2020 NIS-Teen data, only 4.0% of U.S. adolescents initiated HPV vaccination at ages 9–10, but those who did had a 93% series completion rate by age 13, compared to 66% for those starting at ages 11–12.
The Efficacy, Effectiveness, and Safety of Human Papillomavirus (HPV) Vaccines
A narrative review of HPV vaccine studies found that bivalent vaccines are 93–98% effective against cervical lesions, quadrivalent vaccines reduce infections by ~90%, and 9-valent vaccines maintain ≥90% efficacy for 10–12 years, with mild, transient side effects.
Adverse events from HPV vaccination in Taiwan
A retrospective cohort study of 12–15-year-old girls in Taiwan found no statistically significant increase in 19 serious adverse events after HPV vaccination, with fibromyalgia being the most common (73 cases per million).